Harrison.ai: Product Launch

The leadership read

Harrison.Rad 1.5 marks the point where Harrison.ai moved from a detection-first product strategy to a generation-first one. Running approved detection models at clinical scale, over a million patients per month by the company's own account, created the evidentiary base required to make a credible generative-reporting claim. The model is not yet cleared for clinical use; it is in active regulatory submission for the US and EU. That distinction matters operationally: the company now carries a dual-track burden, continued clinical scaling of its existing approved products alongside a multi-jurisdictional regulatory campaign for a categorically different product class, generative reporting rather than flagging. The related signals provided are thin for this specific theme; none of the 12 comparable signals in the last 90 days sits inside medical AI or radiology foundation models, so the pattern read draws on the broader category. Within medical AI, radiology foundation models targeting report generation represent a visible concentration point globally, with activity from both established imaging platforms and AI-native challengers pursuing similar benchmark-then-regulate sequencing. Passing a credentialing exam is a deliberate proof-of-competence signal aimed at clinical audiences and regulators simultaneously, a product-communications choice as much as a technical one. Companies at this stage of multi-jurisdictional regulatory pursuit in clinical AI face rising demand for regulatory affairs leadership with cross-market (FDA, CE-MDR) depth, clinical evidence and outcomes capability able to generate the dossiers that move a research-grade model to cleared product, and commercial leadership experienced in enterprise health system procurement rather than practitioner-level sales.